# Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

> **NCT02948569** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Missouri-Columbia** · enrollment: 12 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** 3-V Bioscience-2640

## Key facts

- **NCT ID:** NCT02948569
- **Lead sponsor:** University of Missouri-Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2017-12-18
- **Final completion:** 2019-01-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948569, "Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02948569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*